Castroville, CA – According to filings with the U.S. Securities and Exchange Commission, Biopharmaceutical Research Co is raising $3,000,000.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, George Hodgin played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Biopharmaceutical Research Co

BRC is a specialty pharmaceutical manufacturing and analytical company focused on plant-based therapeutics and USDA-compliant hemp testing. The company operates a DEA-approved laboratory and is an applicant with DEA to manufacture clean, consistent and compliant cannabis for federally approved researchers across the United States. Our mission is to develop federally compliant active pharmaceutical ingredients for plant-based therapeutics, with uncompromising quality, for patients and researchers everywhere.

To learn more about Biopharmaceutical Research Co, visit http://www.biopharmaresearchco.com/

Contact:
George Hodgin, Chief Executive Officer
831-632-0913
https://www.linkedin.com/in/georgehodgin/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved